AML ETO T821 Gene Rearrangement Quantitative MRD Monitor Test
Introduction to the Test
The AML ETO T821 Gene Rearrangement Quantitative MRD Monitor Test is a specialized molecular diagnostic tool used primarily in the field of hematology. This test plays a crucial role in monitoring minimal residual disease (MRD) in patients diagnosed with acute myeloid leukemia (AML) and other related cancers. By detecting specific genetic markers associated with the disease, healthcare providers can assess the effectiveness of treatment regimens and make informed decisions regarding patient care.
What the Test Measures
This test measures the presence and quantity of the AML ETO T821 gene rearrangement in the patient’s blood or bone marrow. It utilizes advanced Real-Time PCR technology to provide accurate and reliable results, allowing for precise monitoring of MRD levels.
Who Should Consider This Test?
Patients diagnosed with acute myeloid leukemia or those who have undergone treatment for related cancers should consider this test. It is particularly important for individuals experiencing symptoms such as:
- Fatigue
- Unexplained bruising or bleeding
- Frequent infections
- Weight loss
Additionally, those with risk factors such as a family history of blood cancers or previous chemotherapy treatments may also benefit from this test.
Benefits of Taking the Test
- Early detection of disease recurrence
- Monitoring treatment effectiveness
- Guiding further treatment decisions
- Providing peace of mind for patients and families
Understanding Your Results
Results of the AML ETO T821 Gene Rearrangement Quantitative MRD Monitor Test are typically available within a few days. A higher level of MRD may indicate a higher risk of disease recurrence, while a lower level can suggest effective treatment. It is essential to discuss your results with your healthcare provider to understand their implications fully.
Test Pricing
| Price Type | Amount (NGN) |
|---|---|
| Discount Price | 150,000 |
| Regular Price | 200,000 |
Booking the Test
To book the AML ETO T821 Gene Rearrangement Quantitative MRD Monitor Test, please contact us at +2348077798758 or visit our website. Ensure you have a duly filled MRD Requisition form (Form 22) with historical data ready before the test. Samples must be collected in a 5 mL (3 mL min.) whole blood or bone marrow in 1 Lavender Top (EDTA) tube and shipped refrigerated. DO NOT FREEZE.
Turnaround Time
Samples should be submitted on Mondays or Thursdays by 11 AM, and reports will be available on Wednesdays or Saturdays.
Book your test today and take a proactive step in managing your health!
